Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/eurheartj/sux027 http://scihub22266oqcxt.onion/10.1093/eurheartj/sux027 C5520761!5520761!28751838     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+Heart+J+Suppl 2017 ; 19 (Suppl D): D102-12 Nephropedia Template TP {{tp|p=28751838|t=2017. ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure |pdf=|usr=}}{{28751838}} gab.com Text ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure JO: Eur Heart J Suppl http://www.kidney.de/pget.php?&tw=1&pmid=28751838 #FOAvip Biomarkers have dramatically impacted the way heart failure (HF) patients are evaluated and managed. A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological or pathogenic processes, or pharmacological responses to a therapeutic intervention. Natriuretic peptides [B-type natriuretic peptide (BNP) and N-terminal proBNP] are the gold standard biomarkers in determining the diagnosis and prognosis of HF, and a natriuretic peptide-guided HF management looks promising. In the last few years, an array of additional biomarkers has emerged, each reflecting different pathophysiological processes in the development and progression of HF: myocardial insult, inflammation, fibrosis, and remodelling, but their role in the clinical care of the patient is still partially defined and more studies are needed before to be well validated. Moreover, several new biomarkers have the potential to identify patients with early renal dysfunction and appear to have promise to help the management cardio-renal syndrome. With different biomarkers reflecting HF presence, the various pathways involved in its progression, as well as identifying unique treatment options for HF management, a closer cardiologist-laboratory link, with a multi-biomarker approach to the HF patient, is not far ahead, allowing the unique opportunity for specifically tailoring care to the individual pathological phenotype. Twit Text FOAVip ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure ????Eur Heart J Suppl http://www.kidney.de/pget.php?&tw=1&pmid=28751838 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28751838 #FOAvip English Wikipedia <ref>{{Cite pmid|28751838}}</ref> ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure #MMPMID28751838 Aspromonte N; Gulizia MM; Clerico A; Di Tano G; Emdin M; Feola M; Iacoviello M; Latini R; Mortara A; Valle R; Misuraca G; Passino C; Masson S; Aimo A; Ciaccio M; Migliardi M Eur Heart J Suppl 2017[May]; 19 (Suppl D): D102-12 PMID28751838show ga Biomarkers have dramatically impacted the way heart failure (HF) patients are evaluated and managed. A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological or pathogenic processes, or pharmacological responses to a therapeutic intervention. Natriuretic peptides [B-type natriuretic peptide (BNP) and N-terminal proBNP] are the gold standard biomarkers in determining the diagnosis and prognosis of HF, and a natriuretic peptide-guided HF management looks promising. In the last few years, an array of additional biomarkers has emerged, each reflecting different pathophysiological processes in the development and progression of HF: myocardial insult, inflammation, fibrosis, and remodelling, but their role in the clinical care of the patient is still partially defined and more studies are needed before to be well validated. Moreover, several new biomarkers have the potential to identify patients with early renal dysfunction and appear to have promise to help the management cardio-renal syndrome. With different biomarkers reflecting HF presence, the various pathways involved in its progression, as well as identifying unique treatment options for HF management, a closer cardiologist-laboratory link, with a multi-biomarker approach to the HF patient, is not far ahead, allowing the unique opportunity for specifically tailoring care to the individual pathological phenotype. äANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure (epmc).pdf DeepDyve Pubget Overpricing